BGNE BeiGene Ltd.

130.63
+6.8  (+5%)
Previous Close 123.83
Open 126.01
Price To Book 4.86
Market Cap 7814414748
Shares 59,820,981
Volume 233,256
Short Ratio
Av. Daily Volume 290,933

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Tislelizumab
Hepatocellular carcinoma (HCC)
Phase 2 pivotal trial data due late 2019 or early 2020 (China).
Pamiparib (BGB-290)
Ovarian Cancer
Phase 3 data from 17p del cohort due 2H 2019.
Zanubrutinib (BGB-3111) with Bendamustine Plus Rituximab
First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 2 pivotal trial initiation announced November 13, 2017.
BGB-3111 in combination with GAZYVA (obinutuzumab)
Follicular lymphoma (FL)
Phase 3 trial to be initiated 1H 2018.
Pamiparib (BGB-290)
Solid tumors - cancer
Phase 2 pivotial China trial initiation announced July 5, 2017.
BGB-A317
Urothelial cancer (UC) - bladder cancer
Phase 2 data presentation at EHA June 14, 2019, 5:30pm.
Tislelizumab - BGB-A317
Relapsed or refractory classical Hodgkin lymphoma (cHL)
Phase 2 updated data due 1H 2019.
Zanubrutinib (BGB-3111)
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 data due 2H 2019.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab - BGB-A317
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 data due 2019.
Tislelizumab
Hepatocellular carcinoma (HCC) - second-line
Phase 3 trial initiation announced July 24, 2018.
Pamiparib (BGB-290)
Gastric Cancer
Phase 2 China data due 1H 2019.
Tislelizumab
Urothelial carcinoma - Bladder cancer
Phase 3 trial commencement of enrollment announced May 17, 2018.
Pamiparib (BGB-290)
Maintenance Therapy Ovarian Cancer
Phase 3 trial initiation announced July 24, 2018.
Tislelizumab
Non-squamous non-small cell lung cancer (NSCLC)
Phase 3 trial initiation announced August 9, 2018.
Tislelizumab
Squamous non-small cell lung cancer (NSCLC)
Phase 1/2 data presented at SNO November 16, 2018 noted 2/15 partial responses.
Pamiparib (BGB-290)
Glioblastoma (GBM)
Phase 3 data due 2H 2019.
Zanubrutinib (BGB-3111) vs Ibrutinib
Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b initial data due 2H 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab
Gastric Cancer
Phase 1 updated data due at EHA June 14, 2019, 5:30pm.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 2 trial initiation announced February 19, 2019.
Zanubrutinib (BGB-3111) - MAGNOLIA
Marginal Zone Lymphoma
Phase 3 initial China data due at ASCO June 1, 2019, 8am CT.
Tislelizumab
Nasopharyngeal cancer

Latest News

  1. BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
  2. BRIEF-Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
  3. BRIEF-BeiGene Q1 Loss Per Share $0.22
  4. BeiGene Reports First Quarter 2019 Financial Results
  5. Is BeiGene, Ltd. (NASDAQ:BGNE) Trading At A 24% Discount?
  6. BRIEF-Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017
  7. Here’s What Hedge Funds Think About BeiGene, Ltd. (BGNE)
  8. BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
  9. Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal
  10. BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
  11. Does BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Pay Matter?
  12. 3 Key Takeaways From BeiGene's CEO
  13. Be cautious about the market now — and buy these 3 stocks on weakness
  14. BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics
  15. Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
  16. Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson — Fundamental Analysis, Key Performance Indications
  17. BeiGene to Present at Upcoming Investor Conferences
  18. Edited Transcript of BGNE earnings conference call or presentation 27-Feb-19 11:00pm GMT
  19. Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
  20. Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4